AHEAD Medicine develops AI-based diagnostic and clinical decision tools for blood cancer management

AHEAD Medicine develops AI-based diagnostic and clinical decision tools for blood cancer management. Our team has gathered experts in hematology, data science, and machine learning fields to develop tailor-made solutions for the blood cancer diagnosis. Our leading product, AHEAD-flow, is an automated clinical flow cytometry analysis platform, which performs the analysis on clinical flow cytometry exam data (FCS data) 100 times faster than the current analysis standard. AHEAD-flow platform has been selected as the CYTO 2020 Innovation Showcase finalists (CYTO is the annual conference of International Society of Advanced Cytometry). We also have a complimentary diagnosis pipeline in development to support treatment response prediction for blood cancer patients.

Our proof of concept studies have been presented in multiple congresses and peer-review journals. Recently, we are multiple collaboration contract in discussion with lab-medicine companies and medical centers in North America. We are now seeking funding to complete FDA validation studies.

 Booth No. L826